US Patent

US10669236 — Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide

Composition of Matter · Assigned to Athenex HK Innovative Ltd · Expires 2038-09-07 · 12y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects solid forms A, B, and C of the compound 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide.

USPTO Abstract

The present application provides solid Forms A, B, and C of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same. The compounds disclosed herein may be used in the treatment or prevention of a disease or condition in which a tyrosine kinase plays a role.

Drugs covered by this patent

Patent Metadata

Patent number
US10669236
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-09-07
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Athenex HK Innovative Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.